Titan Pharmaceuticals Inc., of South San Francisco, said it priced an underwritten public offering with expected total gross proceeds of $9.5 million. The company's lead product is Probuphine, a long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence.